Sage Journals: Discover world-class research

Abstract

Aims

We studied the association of circulating metabolic biomarkers with asymptomatic left ventricular diastolic dysfunction, a risk-carrying condition that affects 25% of the population.

Methods and results

In 570 randomly recruited people, we assessed in 2005–2010 and in 2009–2013 the multivariable-adjusted correlations of e’ (early left ventricular relaxation) and E/e’ (left ventricular filling pressure) measured by Doppler echocardiography with 43 serum metabolites, quantified by magnetic resonance spectroscopy. In 2009–2013, e’ cross-sectionally increased (Bonferroni corrected p ≤ 0.016) with the branched-chain amino acid valine (per one standard deviation increment, +0.274 cm/s (95% confidence interval, 0.057–0.491)) and glucose+the amino acid (AA) taurine (+0.258 cm/s (0.067–0.481)), while E/e’ decreased (p ≤ 0.017) with valine (–0.264 (–0.496– –0.031)). The risk of developing left ventricular diastolic dysfunction over follow-up (9.4%) was inversely associated (p ≤ 0.0059) with baseline glucose+amino acid taurine (odds ratio, 0.64 (0.44–0.94). In partial least squares analyses of all the baseline and follow-up data, markers consistently associated with better diastolic left ventricular function included the amino acids 2-aminobutyrate and 4-hydroxybutyrate and the branched-chain amino acids leucine and valine, and those consistently associated with worse diastolic left ventricular function glucose+amino acid glutamine and fatty acid pentanoate. Branched-chain amino acid metabolism (–log10 _p = 12.6) and aminoacyl-tRNA biosynthesis (9.9) were among the top metabolic pathways associated with left ventricular diastolic dysfunction.

Conclusion

The associations of left ventricular diastolic dysfunction with circulating amino acids and branched-chain amino acids were consistent over a five-year interval and suggested a key role of branched-chain amino acid metabolism and aminoacyl-tRNA biosynthesis in maintaining diastolic left ventricular function.

Keywords

Biomarker branched-chain amino acids diastolic left ventricular dysfunction metabolomics population science

Get full access to this article

View all access options for this article.

References

Ussher

Elmariah

Gerszten

et al.

The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am Coll Cardiol 2016; 68: 2850–2870.

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–1602.

Dunn

Broadhurst

Deepak

et al.

Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 2007; 3: 413–426.

Cheng

Wang

Shiao

et al.

Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: Diagnostic and prognostic value of metabolomics. J Am Coll Cardiol 2015; 65: 1509–1520.

Hunter

Kelly

McGarrah RW3 et al.

Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: Evidence for shared metabolic impairments in clinical heart failure. J Am Heart Assoc 2016; 5: e003190–e003190.

Riles

Marcos

et al.

Metabolomic profiling in relation to new-onset atrial fibrillation (from the Framingham Heart Study). Am J Cardiol 2016; 118: 1493–1496.

Cheng

Larson

McCabe

et al.

Distinct metabolomic signatures are associated with longevity in humans. Nat Commun 2015; 6: 6791–6791.

Kuznetsova

Herbots

López

et al.

Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009; 2: 105–112.

Kloch-Badelek

Kuznetsova

Sakiewicz

et al.

on behalf of the European Project on Genes in Hypertension (EPOGH) Investigators. Prevalence of diastolic left ventricular dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovascular Ultrasound 2012; 10: 10–10.

10.

Kuznetsova

Thijs

Knez

et al.

Longitudinal changes in left ventricular diastolic dysfunction in a general population. Circ Cardiovasc Imaging 2015; 8: e002882–e002882.

11.

Kuznetsova

Thijs

Knez

et al.

Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Heart Assoc 2014; 3: e000789–e000789.

12.

Zhang

Marrachelli

Thijs

et al.

Diastolic left ventricular function in relation to circulating metabolic biomarkers in a general population. J Am Heart Assoc 2016; 5: e002681–e002681.

13.

Levey

Stevens

Schmid

et al.

for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.

14.

Gottdiener

Bednarz

Devereux

et al.

American Society of Echocardiography recommendations for use of echocardiography in clinical trials. A report from the American Society of Echocardiography's Guidelines and Standard Committee and the Task Force on Echocardiography in Clinical Trials. J Am Soc Echocardiogr 2004; 17: 1086–1119.

15.

Marrachelli

Monleon

Rentero

et al.

Genomic and metabolomic profile associated to microalbuminuria. PLoS One 2014; 9: e98227–e98227.

16.

Dona

Coffey

Figtree

. Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment. Eur J Prev Cardiol 2016; 23: 1578–1589.

17.

Kunutsor

Laukkanen

Bluemke

et al.

Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence. Eur J Prev Cardiol 2016; 23: 1354–1362.

18.

Brown

Perry

Allen

et al.

Mitochondrial function as a therapeutic target in heart failure. Nature Rev Cardiol 2017; 14: 238–250.

19.

Reitzer

Wice

Kennell

. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979; 254: 2669–2676.

20.

Phang

Liu

Hancock

et al.

Proline metabolism and cancer: Emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care 2015; 18: 71–77.

21.

Huang

Zhou

et al.

Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit?

Cardiovasc Res 2011; 90: 220–223.

22.

Harper

Miller

Block

. Branched-chain amino acid metabolism. Annu Rev Nutr 1984; 4: 409–454.

23.

Newgard

Bain

et al.

A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311–326.

24.

Tanada

Shioi

Kato

et al.

Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. Life Sci 2015; 137: 20–27.

25.

D'Antona

Ragni

Cardile

et al.

Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. Cell Metab 2010; 12: 362–372.

26.

Sun

Olson

Gao

et al.

Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 2016; 133: 2038–2049.

27.

Sun

She

et al.

Protein phosphatase 2 Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells. J Clin Invest 2009; 119: 1678–1687.

28.

Beyranvand

Khalafi

Roshan

et al.

Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol 2011; 57: 333–337.

29.

Dello

Neis

de Jong

et al.

Systematic review of ophthalmate as a novel biomarker of hepatic glutathione depletion. Clin Nutr 2013; 32: 325–330.

30.

Irino

Toh

Nagao

et al.

2-Aminobutyric acid modulates glutathione homeostasis in the myocardium. Sci Rep 2016; 9: 36749–36749.

31.

Fedak

Bernal

Capashaw

et al.

Applying the Bradford Hill criteria in the 21st century: How data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol 2015; 12: 14–14.

32.

Czibik

Steeples

Yavari

et al.

Citric acid cycle intermediates in cardioprotection. Circ Cardiovasc Genet 2014; 7: 711–719.

33.

Griffin

Atherton

Shockcor

et al.

Metabolomics as a tool for cardiac research. Nat Rev Cardiol 2011; 8: 630–643.

34.

Knez

Salvi

Tikhonoff

et al.

Left ventricular diastolic function associated with common genetic variation in ATP12A in a general population. BMC Med Genet 2014; 15: 121–121.

35.

Zhang

Ravassa

Yang

et al.

Diastolic left ventricular function in relation to urinary and serum collagen biomarkers in a general population. PLoS One 2016; 11: e0167582–e0167582.

36.

Ravassa

Kuznetsova

Varo

et al.

Biomarkers of cardiomyocyte injury and stress identify left atria and left ventricular remodelling and dysfunction: A population-based study. Int J Cardiol 2015; 185: 177–185.

37.

Zhang

Staessen

Thijs

et al.

Left ventricular diastolic function in relation to the urinary proteome: A proof-of-concept study in a general population. Int J Cardiol 2014; 176: 158–165.

38.

Zhang

Nkuipou-Kenfack

Yang

et al.

Epidemiologic observations guiding clinical application of the HF1 urinary peptidomic marker of diastolic left ventricular dysfunction. J Am Soc Hypertens 2018; 12: 438–447.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.36 MB

Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study

Abstract

Aims

Methods and results

Conclusion

Keywords

Get full access to this article

References

Supplementary Material